Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

• Conditions: Myelogenous Leukemia, Chronic

• Registration Number: NCT00038597
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.

Detailed Description

Objectives for this study are two-fold:

1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated phase CML in relation to response rate, duration of response, and survival.

2. To assess the toxicity of SCH66366 in these patients.

Study Timeline

• Study Start: 2001-04-30
• Study First Submitted: 2002-06-03
• Study First Submitted QC: 2002-06-03
• Study First Posted: 2002-06-04
• Primary Completion: 2004-05-07
• Study Completion: 2004-05-07
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-29
• Last Update Posted: 2018-10-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

MDAnderson Cancer Center; 🇺🇸 Houston, Texas, United States